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Narcolepsy is a disease in which there is diurnal excessive sleepiness with sleep attacks
and a prevalence in the general population of 1/4000 individuals. Classically, it is
characterized by cataplexy, sleep paralysis, hypnagogic hallucinations and fragmented
sleep. The use of modaﬁnil in the treatment of narcolepsy is the ﬁrst option of treatment
for diurnal excessive sleepiness.
Although considered a safe drug for use in patients with narcolepsy, being utilized for
more than 20 years, modaﬁnil possesses a series of side effects, some of them still not fully
researched or described.
Side effects such as headache, nausea, anxiety, insomnia, lumbago, diarrhea, dyspep-
sia, rhinitis and vertigo are the most frequent. However, the clinical follow-up of patients
under treatment with modaﬁnil must be intensive and the side effects ought to be noted
and evaluated. The under-response to treatment or the unexpected side effects must
always be directed to differential diagnostics.
The objective of this article is to describe an unexpected side effect of the use of
modaﬁnil in a patient with incorrect diagnosis of narcolepsy.
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Narcolepsy is a chronic disease in which there is excessive
sleepiness (ES) with sleep attacks and with a prevalence of 1/
4000 individuals in the general population. It is classically
characterized by ES, cataplexy (loss of muscle tonus), sleep
paralysis (body immobility during the transition awake/sleep
cycle), hypnagogic hallucinations (dreams during the awake/
sleep transition cycle) and fragmented sleep [1,2].
Narcolepsy may be mono-symptomatic (only ES) or oligo-
symptomatic (ES and cataplexy). The degree of ES is variable
and the attacks of cataplexy might involve several muscle
groups being triggered by emotions [1,3].
The use of modaﬁnil in the treatment of narcolepsy is a ﬁrst
option for the treatment of diurnal excessive sleepiness (DES)
in patients with narcolepsy. Modaﬁnil shows several advan-
tages when compared with the other stimulants due to smaller
cardiovascular alterations and smaller risk of addiction [4].
Modaﬁnil is a stimulant, of the non-amphetamine type, with
agonist action upon the hypocretin-1 system, besides blocking
the dopamine and norepinephrine transport [4].
Other indications of modaﬁnil are for the treatment of
idiopathic hypersomnia or even for residual somnolence in
patients with Sleep Obstructive Apnea Syndrome (SOAS).
However, there are no studies on the safety and side effects
in these groups of patients [5].
Although being considered a safe drug for use in patients
with narcolepsy, already being utilized for more than 20
years, modaﬁnil presents a series of possible side effects,
some of them still not fully studied and described [4].
The objective of this article is to describe an unusual side
effect of the use of modaﬁnil in a patient misdiagnosed with
narcolepsy.2. Clinical case
A 58-year-old male patient searched for medical treatment 3
years ago, with an anamnestic case characterized by diurnal
excessive sleepiness with progressive worsening. This was
associated with sound snoring and apneas, as perceived by
his partner. He did not have parasomnia, previous somno-
lence, cataplexy or any other sleep disorder. The patient did
not show family or personal history of any neurological
degenerative diseases and the neurological exam was com-
pletely normal. As co-morbidities the patient demonstrated
overweight (IMC¼29), systemic arterial hypertension and
dyslipidemia.
At the beginning of the investigation (performed in other
medical facilities), a polysonogram was performed with
inadequate protocol and its result led to a false negative
diagnosis for SOAS. As per this negative result and the
intense patient symptomatology (Epworth index of 18 at the
time), we began the modaﬁnil treatment with 100 mg/day
with a diagnostic hypothesis of idiopathic hyper-somnolence
or even narcolepsy. The patient developed loss of muscle
tonus with a consequent fall in situations of happiness or
sadness, without loss of consciousness and with a maximum
duration of 2 min after beginning this medication, thuscharacterizing a case of cataplexy. Due to the presence of
this symptom and owing to the little improvement upon the
sleepiness symptom, the drug dosage was increased to
200 mg/day of modaﬁnil, with additional worsening of the
clinical picture. The patient demonstrated during this period
an average of 12 episodes of cataplexy per day with intense
social impairment. After 3 months of treatment with mod-
aﬁnil, the drug was discontinued with prompt resolution of
the cataplexy.
Polysonogram performed posteriorly with adequate pro-
tocol resulted in a severe case of SOAS. Basal polysonogram
presented an index of respiratory disorder of 39.4 events/h
and exam's minimal saturation of 64%. The test of multiple
latencies of sleep (MLST) conﬁrmed the hyper-sleepiness
(average latency was 1.2 min for sleep) and did not demon-
strate the presence of REM sleep in any of the opportunities.
We initiated a treatment with CPAP (titrated in laboratory
with a pressure of 7 cmH2O) with clinically marked improve-
ment and resolution of the excessive sleepiness.3. Discussion
The diagnosis of SOAS is much more frequent than that of
narcolepsy. We estimate that it may be over 30% in terms of
prevalence of SOAS in the general population and that the
one for narcolepsy is around only 0.02% [6]. However, DES is a
common factor among these 2 disorders. Some clinical
characteristics, such as the presence of cataplexy, age of
onset of symptoms, hallucinations and sleep paralysis, do
help us diagnose narcolepsy. Moreover, complementary
exams such as full night sonogram, MLST, dosage of the
allele HLA-DQB1n0602 and the level of hypocretin-1 also help
us in differential diagnosing [1].
A well-done polysonogram within the recommended Bra-
zilian Association of Sleep's criteria gives us the diagnosis of
SOAS [7]. However, the association of the 2 diseases may
happen and the initial treatment of SOAS is thus mandatory
for posterior evaluation of the signs and symptoms of narco-
lepsy. In this described case, the patient was not initially and
adequately investigated. The false-negative polysonogram and
the absence of MLST were the main factors leading to the
mischaracterization of a narcolepsy case.
Narcolepsy with cataplexy is generally treated with drugs
that produce an increase in awareness and with antidepres-
sants that control cataplexy [1]. Modaﬁnil has been the drug
of ﬁrst choice in narcolepsy and idiopathic hypersomnia [4].
Other indications for the use of this drug are treatment of
sleepiness and fatigue related to neurological and psychiatric
diseases, attention deﬁcit, sleep control in night workers and
residual sleepiness in SOAS being treated with CPAP [5].
Although safe, the use of modaﬁnil for the clinical treat-
ment of ES in patients with narcolepsy must always be
preceded by a very careful and complete clinical and com-
plementary evaluation for the deﬁnition of the diagnostic and
therapeutical indication. The clinical follow-up of these
patients during the use of modaﬁnil must be intensive and
the side effects must be closely scrutinized [8].
The little treatment response or unexpected side effects
must always point to possible differential diagnosis. In this
S l e e p S c i e n c e 7 ( 2 0 1 4 ) 4 7 – 4 9 49case, the absence of the use of some substances such as
tricyclic antidepressants might have led to cataplexy, besides
the association with another sleep disorder, which is always
a possibility to be kept in mind [9–11].
The patient did not present any clinical characteristic
suggestive of narcolepsy, did not show the allele HLA-
DQB1n0602 and improved completely regarding the cataplexy
episodes after modaﬁnil withdrawal.
The abovementioned case show us a probable and unu-
sual side effect of the use of modaﬁnil, with worsening of
cataplexy, in a patient with diagnosis of SOAS erroneously
misinterpreted as a case of narcolepsy [12,13]. This case
strengthens the need of a complementary and correct inves-
tigation, aimed at the clinical suspicion, besides the revision
of the original diagnosis when the treatment does not lead to
improvement or even worsens the symptoms.
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